Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological disorder slowed progress of the condition in a clinical trial.
More Stories
U.S. business activity suffers small loss of momentum in September, PMI shows
Optimism about the outlook in the year ahead deteriorated sharply to the lowest level since October 2022, in part due...
Trump’s social-media stock ‘DJT’ drops ahead of insider stock-sale filing deadline
U.S. Securities law requires a Form 4 filing within two business days of an insider stock sale.
Nvidia’s stock is no longer the S&P 500’s top gainer this year. Here’s what is.
Investors have been turning beyond the chip sector as a way to play the AI and data-center booms.
J.D. Vance warns of deliberate ‘bond-market death spiral’ if Trump is elected
“Do the international investors, the people who are getting rich off globalization, the people who have gotten rich from shipping...
Bank of America on track to open 40 new branches this year
While more customers are doing their banking online, bank branches are still being added and renovated for customers to meet...
Treasury yields climb as traders bet on another jumbo Fed rate cut
Yields on long-dated Treasurys drifted higher on Monday as traders bet that the Federal Reserve would deliver at least one...